Cytosorbents Corp 8-K Summary: 2025 Annual Meeting Results
Business Context and Reporting Period
Cytosorbents Corporation (Nasdaq: CTSO) filed this Form 8-K on June 12, 2025, to report the results of its 2025 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
At the Annual Meeting, 40,071,481 shares were represented, constituting a quorum out of 62,610,376 outstanding shares. All three proposals submitted to stockholders were approved:
- Proposal 1 (Election of Directors): Five directors were elected to serve until the 2026 Annual Meeting. While all nominees received a majority of votes cast, significant "Against" votes were recorded for several directors, ranging from approximately 913,647 to 3,319,370 shares.
- Proposal 2 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers. The vote was 18,189,951 For, 1,720,512 Against, and 2,741,091 Abstain.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of WithumSmith+Brown, PC, as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 39,485,868 For, 553,680 Against, and 31,933 Abstain.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the specific reasons for the significant "Against" votes on the director election, particularly for Alan D. Sobel (3.3M against) and Michael Bator (2.7M against).
- Confirm the total number of broker non-votes (17,419,927) and their impact on the effective voting power of the proposals.
- Review the Company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.
- Note that the auditor ratification covers the fiscal year ending December 31, 2025.